GrowthCurve Backs TailorMed With Majority Investment

Patient support programs need a way into the places where treatment decisions become administrative work. TailorMed has been building that route through hospitals, clinics and pharmacies, connecting assistance resources to the teams and patients who can use them.

On November 2, 2026, TailorMed announced a majority investment from GrowthCurve Capital. The New York private equity firm is backing the company's expansion across medication access, affordability and adherence, with further product development and AI capabilities among the stated priorities. Financial terms were not disclosed.

The investment puts an established healthcare network inside an ownership model built around developing data-rich businesses. For providers and pharmacies, the practical consequence sits closer to the next patient application: TailorMed is expanding the range of work it wants to help complete after a prescription is written.

What GrowthCurve's TailorMed investment supports

GrowthCurve's healthcare investing head Vignesh Aier and director Robert Thwaits are named in the announcement, which emphasizes TailorMed's network and continued platform investment. Leerink Partners and TripleTree advised TailorMed on the transaction. The release identifies a majority investment without supplying a purchase price, exact ownership percentage or separate regulatory and closing timetable.

GrowthCurve Capital describes an investment strategy built around proprietary data, network effects and businesses embedded in important customer work. Its operating support includes AI, product and engineering, and human capital. TailorMed fits that stated preference through relationships that connect multiple healthcare participants rather than through a single isolated software function.

That fit helps explain the strategic logic without requiring a speculative valuation. An investor can fund another product feature; finding a useful place for that feature inside a provider's existing work is a different assignment. TailorMed arrives with institutional connections through which additional capabilities can reach users, while GrowthCurve brings an operating approach aimed at developing those capabilities.

How TailorMed connects care teams and patients

TailorMed's product design makes the coordination problem visible. TailorMed Core brings financial-navigation work into a care-team system, covering eligibility, enrollment, claims, renewals and tracking. The company's description includes organizing work in queues, capturing documentation and keeping patient and program information connected to health-system technology.

For a care team, an eligible patient creates a chain of assignments. Someone has to recognize the need, find a suitable resource, assemble the application and know whether it has moved forward. When those steps live in separate systems, the patient and the staff member can each be waiting for action that belongs somewhere else. TailorMed is selling a way to make that responsibility easier to follow.

TailorMed Connect extends the process to patients through self-service enrollment, support resources and a view of available financial assistance. TailorMed says this patient-facing experience works alongside Core so care teams can see patient activity. That relationship matters because asking a patient to act independently still leaves a provider responsible for understanding where the process stands.

The wider suite includes Complete, which combines technology with expert services; Amplify, aimed at manufacturer access solutions; and Alliance, a set of partner offerings. Together, those products describe the company's broader commercial ambition. TailorMed wants a continuing role across the medication journey, with software, services and patient participation sharing more of the same context.

The network behind the medication-access business

TailorMed reports connections spanning more than 950 hospitals, 4,700 clinics and 3,100 pharmacies in its November announcement. It also reports more than 100 life-sciences programs and 6,000 support programs. Those are company-reported measures of network reach, which help explain the distribution opportunity without establishing how every institution uses every product.

The company says it has secured more than $7.4B in financial assistance since 2020. That measure concerns assistance for patients; it is neither TailorMed revenue nor the consideration paid by GrowthCurve. Keeping the accounting clear lets the operating achievement be assessed on its own terms, instead of turning patient support into an invented deal valuation.

A May 2026 partnership with Flatiron Health offers a concrete example of how TailorMed seeks distribution. The company joined the Flatiron Vendor Network to make medication support available across oncology providers' workflows. The announcement described financial assistance, support programs and adherence resources reaching practices through an environment their teams already use.

For healthcare buyers, that route has commercial significance. Another standalone destination can create another place to check; a service available within an existing working relationship has a chance to meet staff while they are handling the patient. The implementation work still belongs to real organizations, with their own systems, responsibilities and capacity. Broader reach increases the number of relationships TailorMed must keep coordinated.

TailorMed occupies a part of healthcare software where patient access and institutional finances are closely linked. DevCuration's earlier coverage of Atlas Health's patient-affordability business describes a related buying problem, while Midstream Health's financial-operations platform addresses another part of a hospital's administrative workload.

From financial navigation to a broader operating role

TailorMed's expansion predates the GrowthCurve investment. Its 2024 financing announcement described $40M combining equity and debt, led by Windham Capital Partners, with Poalim-tech leading the debt facility. The company was already framing affordability as an entry point into a longer stretch of medication access and ongoing support.

Earlier, a September 2021 round extension brought a Providence Ventures-led financing to $25M. BrightEdge, OSF Ventures and Citi Impact Fund were among the additional strategic investors named. The extension was a new total for that round, so treating it as a separate $25M on top of the original financing would overstate the record.

Co-founders Srulik Dvorsky, CEO, and Adam Siton, CTO, now carry that expansion into a majority-investment relationship. Their current leadership and company account describe a business shaped by the difficulty of navigating care for seriously ill relatives. The operating response has grown from financial navigation toward a platform covering more of the work around treatment.

For a pharmacy or health system evaluating TailorMed, the broader scope places more weight on how assignments survive between teams and between visits. A patient can finish one application while another enrollment, renewal or support need is already approaching. GrowthCurve's backing follows TailorMed into those continuing responsibilities, where the work keeps arriving long after the initial match to a program.